Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
收藏数据链接：
官方服务：
资源简介：
Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.
创建时间：
2023-09-15
